Supplementary Fig. 7: DRPB inhibition in mouse/human duodenum organoid and in vivo phenotype following DRPB injections.

a, b, Representative bright-field images of mouse (a) and human (b) duodenal organoids expanded for 7 days and 10 days, respectively, using standard submerged Matrigel in medium containing ENR (EGF/Noggin/R-spondin) with different Fz-subtype-specific DRPB antagonist treatments at serial concentrations from 0.1–100 nM. Each Fz antagonist was replenished every 3 days during medium change. In vitro experiments were repeated at least three times, and representative images are shown. Scale bars, 100 μm. c, Representative H & E stained sections of jejunum cross-sections from mice that received PBS or recombinant Fz-subtype-specific DRPB antagonists (conjugated with mouse serum albumin) at a concentration of 15 mg/kg once a day for 5 days. This experiment was performed once due to the protein yield limitation of mouse serum albumin conjugated DRBPs. The in vivo phenotype experiments are repeated using adenoviral delivery of DRBPs, with results shown in Fig. 4. Scale bar, 50 μm.